References
- Christophers E., Mrowietz U. Psoriasis. Fitzpatrick's dermatology in general medicine, 6th ed, I. M Freedberg, A. Z Eisen, K Wolff, K Frank Austen, L. A Goldsmith, S. I Katz. McGraw Hill, New York 2003; 407–27
- Gottlieb A. B. Psoriasis: Emerging therapeutic strategies. Nat Rev Drug Discov 2005; 4: 19–34
- Esposito M., Saraceno R., Giunta A., Maccarone M. An Italian study on psoriasis and depression. Dermatology 2006; 212: 123–7
- Chimenti S. Topical treatments. 2005; 15: 137–56, In: Psoriasis SEE: Societa Editrice Europea, Florence, Italy
- Lebwohl M. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol 2005; 53: S59–69
- Gottlieb A., Ford R. O., Spellman M. C. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque‐type psoriasis of nonscalp region. J Cutan Med Surg 2003; 7: 185–92
- Lebwohl M., Sherer D., Washenik K., Krueger G. G., Menter A., Koo J., et al. A randomized, double‐blind, placebo‐controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 2002; 41: 269–74
- Bergstrom K. G., Arambula K., Kimball A. B. Medication formulation affects quality of life: A randomized single‐blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003; 72: 407–11
- Franz T. J., Parsell D. A., Myers J. A., Hannigan J. F. Clobetasol propionate foam 0.05%: A novel vehicle with enhanced delivery. Int J Dermatol 2000; 39: 535–8
- Franz T. J., Lehman P. A., Feldman S. R., Spellman M. C. Bioavailability of clobetasol propionate in different vehicles. Skin Pharmacol Appl Skin Physiol 2003; 16: 212–16
- Fredriksson T., Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978; 157: 238–44